A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: The production of nitric oxide

Molecular Cancer Therapeutics

Volumn 1, Issue 12, 2002, Pages 1009-1017

  Simeone, Ann Marie ^a   Ekmekcioglu, Suhendan ^a   Broemeling, Lyle D ^a   Grimm, Elizabeth A ^a   Tari, Ana M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FENRETINIDE; GAMMA INTERFERON; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CULTURE; CELL DIVISION; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; ENZYME INHIBITORS; FENRETINIDE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0242484107     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Sheikh, M., Shao, Z-M., Li, X-S., Ordonez, J., Conley, B., Wu, S., Dawson, M., Han, Q-X., Chao, W-R., Quick, T., Niles, R., and Fontana, J. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis (Lond.), 16: 2477-2486, 1995.
2. Wang, T. T., and Phang, J. M. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett., 107: 65-71, 1996. (Pubitemid 26370859)
3. Herbert, B., Sanders, B., and Kline, K. N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-β and induction of apoptosis in human breast cancer cells. Nutr. Cancer, 34: 121-132, 1999. (Pubitemid 29511108)
4. Vaccari, M., Silingardi, P., Argnani, A., Horn, W., Giungi, M., Mascolo, M. G., Grilli, S., and Colacci, A. In vitro effects of fenretinide on cell-matrix interactions. Anticancer Res., 20: 3059-3066, 2000.
5. Moon, R. C., Thompson, H. J., Becci, P. J, Grubbs, C. J., Gander, R. J., Newton, D. L., Smith, J. M., Phillips, S. L., Henderson, W. R., Mullen, L. T., Brown, C. C., and Sporn, M. B. N-(4-Hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in rat. Cancer Res., 39: 1339-1351, 1979.
6. Costa, A., Malone, W., Perloff, M., Buranelli, F., Campa, T., Dossena, G., Magni, A., Pizzichetta, M., Andreoli, C., Del Vecchio, M., Formelli, F., and Barbieri, A. Tolerability of the synthetic retinoid fenretinide (HPR). Eur. J. Cancer Clin. Oncol., 25: 805-808, 1989. (Pubitemid 19164323)
7. Mehta, R. G., Moon, R. C., Hawthorne, M., Formelli, F., and Costa, A. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur. J. Cancer, 27: 138-141, 1991.
8. Formelli, F., Clerici, M., Campa, T., Di Mauro, M., Magni, A., Mascotti, G., Moglia, D., De Palo, G., Costa, A., and Veronesi, U. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J. Clin. Oncol., 11: 2036-2042, 1993. (Pubitemid 23304631)
9. Veronesi, U., De Palo, G., Marubini, E., Costa, A., Formelli, F., Mariani, L., Decensi, A., Camerini, T., Del Turco, M. R., Di Mauro, M. G., Muraca, M. G., Del Vecchio, M., Pinto, C., D'Aiuto, G., Boni, C., Campa, T., Magni, A., Miceli, R., Perloff, M., Malone, W. F., and Sporn, M. B. Randomized trial of fenretinide to prevent secondary breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. (Bethesda), 91: 1847-1856, 1999.
10. Decensi, A., Bonanni, B., Guerrieri-Gonzaga, A., Torrisi, R., Manetti, L., Robertson, C., De Palo, G., Formelli, F., Costa, A., and Veronesi, U. Chemoprevention of breast cancer: the Italian experience. J. Cell Biochem., 77: 84-96, 2000. (Pubitemid 30176738)
11. Modiano, M., Dalton, W., Lippman, S., Joffe, L., Booth, A., and Meyskens, F., Jr. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Investig. New Drugs, 8: 317-319, 1990. (Pubitemid 20267734)
12. Coradini, D., Biffi, A., Pellizzaro, C., Pirronello, E., and Di Fronzo, G. Combined effect of tamoxifen or interferon-β and 4- hydroxyphenylretinamide on the growth of breast cancer cell lines. Tumour Biol., 18: 22-29, 1997. (Pubitemid 26423281)
13. Lindner, D., and Borden, E. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J. Interferon Cytokine Res., 17: 681-693, 1997. (Pubitemid 27518010)
14. Ratko, T., Detrisac, C., Dinger, N., Thomas, C., Kelloff, G. J., and Moon, R. C. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res., 49: 4472-4476, 1989. (Pubitemid 19208347)
15. Moon, R. C., Mehta, R., and Detrisac, C. Retinoids as chemopreventive agents for breast cancer. J. Steroid Biochem. Mol. Biol., 39: 455-460, 1992.
16. Kelloff, G. J., Crowell, J. A., Boone, C. W., Steele, V. E., Lubet, R. A., Greenwald, P., Alberts, D. S., Covey, J. M., Doody, L. A., Knapp, G. G., Mayfield, S., Parkinson, D. R., Prasad, V. K., Prorok, P. C., Sausville, E. A., and Sigman, C. C. Clinical development plan: tamoxifen. J. Cell. Biochem. Suppl., 20: 252-267, 1994.
17. Singletary, S., Atkinson, E., Hoque, A., Sneige, N., Sahin, A., Fritsche, H. J., Lotan, R., Lu, T., Hittelman, W., Bevers, T., Stelling, C., and Lippman, S. Phase II clinical trial of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen administration before definitive surgery for breast neoplasia. Clin. Cancer Res., 8: 2835-2842, 2002. (Pubitemid 35025727)
18. Zujewski, J., Pai, L., Wakefield, L., Giusti, R., Dorr, F. A., Flanders, C., Caruso, R., Kaiser, M., Goodman, L., Merino, M., Gossard, M., Noone, M. A., Denicoff, A., Venzon, D., Cowan, K. H., and O'Shaughnessy. J. A. Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res. Treat., 57: 277-283, 1999.
19. Fanjul, A., Delia, D., Pierotti, M., Rideout, D., Qiu, J., and Pfahl, M. 4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J. Biol. Chem., 271: 22441-22446, 1996. (Pubitemid 26304679)
20. Kazmi, S., Plante, R., Visconti, V., and Lau, C. Comparison of N-(4-hydroxyphenyl) retinamide and all-trans retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res., 56: 1056-1062, 1996. (Pubitemid 26065400)
21. Clifford, J. L., Menter, D. G., Wang, M., Lotan, R., and Lippman, S. M. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl) retinamide in F9 embryonal carcinoma cells. Cancer Res., 59: 14-18, 1999. (Pubitemid 29062947)
22. Bednarek, A., Shilkaitis, A., Green, A., Lubet, R., Kelloff, G. J., Christov, K., and Aldaz, C. Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors. Carcinogenesis (Lond.), 20: 879-883, 1999. (Pubitemid 29191870)
23. Soria, J. C., Moon, C., Wang, L., Hittelman, W. N., Jang, S. J., Sun, S. Y., Lee, J. J., Liu, D., Kurie, J. M., Morice, R. C., Lee, J. S., Hong, W. K., and Mao, L. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J. Natl. Cancer Inst. (Bethesda), 93: 1257-1263, 2001. (Pubitemid 32816200)
24. Torrisi, R., Mezzetti, M., Johansson, H., Barreca, A., Pigatto, F., Robertson, C., and Decensi, A. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I. IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int. J. Cancer, 87: 601-605, 2000. (Pubitemid 30639823)
25. Decensi, A., Johansson, H., Miceli, R., Mariani, L., Camerini, T., Cavadini, E., Di Mauro, M., Barreca, A., Gonzaga, A., Diani, S., Sandri, M., De Palo, G., and Formelli, F. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer. Cancer Epidemiol. Biomark. Prev., 10: 1047-1053, 2001. (Pubitemid 32959151)
26. Delia, D., Aiello, A., Meroni, L., Nicolini, M., Reed, J. C., and Pierotti, M. A. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis (Lond.), 18: 943-948, 1997. (Pubitemid 28132338)
27. Oridate, N., Suzuki, S., Higuchi, M., Mitchell, M., Hong, W., and Lotan, R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide- induced apoptosis in cervical carcinoma cells. J. Natl. Cancer Inst. (Bethesda), 89: 1191-1198, 1997. (Pubitemid 27350028)
28. Sun, S-Y., Yue, P., and Lotan, R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol. Pharmacol., 55: 403-410, 1999. (Pubitemid 29128096)
29. Sun, S-Y., Li, W., Yue, P., Lippman, S., Hong, W., and Lotan, R. Mediation of N-(4-hydroxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res., 59: 2493-2498, 1999. (Pubitemid 29242302)
30. Suzuki, S., Higuchi, M., Proske, R., Oridate, N., Hong, W., and Lotan, R. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene, 18: 6380-6387, 1999.
31. Hail, N. Jr and Lotan, R. Mitochondrial permeability transition is a central coordinating event in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Cancer Epidemiol. Biomark. Prev., 9: 1293-1301, 2000. (Pubitemid 32044797)
32. Hail, N., Jr., and Lotan, R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl) retinamide. J. Biol. Chem., 276: 45614-45621, 2001.
33. Maurer, B., Metelitsa, L., Seeger, R., Cabot, M., and Reynolds, C. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J. Natl. Cancer Inst. (Bethesda), 91: 1138-1146, 1999. (Pubitemid 29330552)
34. Maurer, B., Melton, L., Billups, C., Cabot, M., and Reynolds, C. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. (Bethesda), 92: 1897-1909, 2000. (Pubitemid 32036920)
35. DiPietrantonio, A. M., Hsieh, T. C., Juan, G., Traganos, F., Darzynkiewicz, Z., and Wu, J. M. Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation. Cancer Res., 60: 4331-4335, 2000. (Pubitemid 32103605)
36. Bani, D., Masini, E., Bello, M. G., Bigazzi, M., and Sacchi, T. B. Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. Cancer Res., 55: 5272-5275, 1995.
37. Adami, A., Crivellente, F., De Prati, A. C., Cavalieri, E., Cuzzolin, L., Tommasi, M., Suzuki, H., and Benoni, G. Biotransformation and cytotoxic properties of NO-donors on MCF7 and U251 cell lines. Life Sci., 63: 2097-2105, 1998. (Pubitemid 28527110)
38. Binder, C., Schulz, M., Hiddemann, W., and Oellerich, M. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-α-induced apoptosis in MCF-7 and other epithelial tumor cells. Lab. Investig., 79: 1703-1712, 1999. (Pubitemid 30013933)
39. Reveneau, S., Arnould, L., Jolimoy, G., Hilpert, S., Lejeune, P., Saint-Giorgio, V., Belichard, C., and Jeannin, J. F. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab. Investig., 79: 1215-1225, 1999. (Pubitemid 29489446)
40. Umansky, V., Ushmorov, A., Ratter, F., Chlichlia, K., Bucur, M., Lichtenauer, A., and Rocha, M. Nitric oxide-mediated apoptosis in human breast cancer cells requires changes in mitochondrial functions and is independent of CD95 (APO-1/Fas). Int. J. Oncol., 16: 109-117, 2000.
41. Alalami, O., and Martin, J. H. ZR-75-1 human breast cancer cells: expression of inducible nitric oxide synthase and effect of tamoxifen and phorbol ester on nitric oxide production. Cancer Lett., 123: 99-105, 1998. (Pubitemid 28046216)
42. Martin, J. H., Alalami, O., and Yaqoob, F. Differential effects of retinoids on nitric oxide production by promonocytic U937 cells and ZR-75-1 human breast cancer cells. Oncol. Rep., 7: 219-223, 2000.
43. Tari, A. M., Hung, M-C., Li, K., and Lopez-Berestein, G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene, 18: 1325-1332, 1999. (Pubitemid 29094884)
44. Ekmekcioglu, S., Ellerhorst, J., Smid, C. M., Prieto, V. G., Munsell, M., Buzaid, A. C., and Grimm, E. A. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin. Cancer Res., 6: 4768-4775, 2000. (Pubitemid 32110418)
45. Swanson, B., Zaharevitz, D., and Sporn, M. Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans retinamide in rats. Drug Metab. Dispos., 8: 168-172, 1980.
46. Widschwendter, M., Daxenbichler, G., Bachmair, F., Muller, E., Zeimet, A. G., Windbichler, G., Uhl-Steidl, M., Lang, T., and Marth, C. Interaction of retinoic acid and interferon-α in breast cancer cell lines. Anticancer Res., 16: 369-374, 1996. (Pubitemid 26128493)
47. Shang, Y., Baumrucker, C. R., and Green, M. H. c-Myc is a major mediator of the synergistic growth inhibitory effects of retinoic acid and interferon in breast cancer cells. J. Biol. Chem., 273: 30608-30613, 1998. (Pubitemid 28545539)
48. Moon, R. C., Kelloff, G. J., Detrisac, C. J., Steele, V. E., Thomas, C. F., and Sigman, C. C. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res., 12: 1147-1153, 1992.
49. Xu, W., Liu, L., Smith, G. C., and Charles, G. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat. Cell Biol., 2: 339-345, 2000.
50. Orucevic, A., Bechberger, J., Green, A. M., Shapiro, R. A., Billiar, T. R., and Lala, P. K. Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int. J. Cancer, 81: 889-896, 1999. (Pubitemid 29249973)
51. Jadeski, L. C., Hum, K. O., Chakraborty, C., and Lala, P. K. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int. J. Cancer, 86: 30-39, 2000. (Pubitemid 30133983)
52. Li, L. M., Kilbourn, R. G., Adams, J., and Fidler, I. J. Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res., 51: 2531-2535, 1991.
53. Dong, Z., Staroselsky, A. H., Qi, X., Xie, K., and Fidler, I. J. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res., 54: 789-793, 1994. (Pubitemid 24068338)
54. Xie, K., Huang, S., Dong, Z., Juang, S. H., Gutman, M., Xie, Q. W., Nathan, C., and Fidler, I. J. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med., 181: 1333-1343, 1995.
55. Thomsen, L. L., Miles, D. W., Happerfield, L., Bobrow, L. G., Knowles, R. G., and Moncada, S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer, 72: 41-44, 1995.
56. Tschugguel, W., Schneeberger, C., Unfried, G., Czerwenka, K., Weninger, W., Mildner, M., Gruber, D. M., Sator, M. O., Waldhor, T., and Huber, J. C. Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. Breast Cancer Res. Treat., 56: 145-151, 1999. (Pubitemid 29494832)
57. De Paepe, B., Verstraeten, V. M., De Potter, C. R., and Bullock, G. R. Increased angiotensin II type-2 receptor density in hyperplasia. DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem. Cell Biol., 117: 13-19, 2002. (Pubitemid 34507530)
58. Vakkala, M., Kahlos, K., Lakari, E., Paakko, P., Kinnula, V., and Soini, Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin. Cancer Res., 6: 2408-2416, 2000. (Pubitemid 30399209)
59. Duenas-Gonzalez, A., Isales, C. M., del Mar Abad-Hernandez, M., Gonzalez-Sarmiento, R., Sangueza, O., and Rodriguez-Commes, J. Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. Mod. Pathol., 10: 645-649, 1997.
60. May, F. E., Johnson, M. D., Wiseman, L. R., Wakeling, A. E., Kastner, P., and Westley, B. R. Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines. J. Steroid Biochem., 33: 1035-1041, 1989. (Pubitemid 20036135)
61. Zeillinger, R., Tantscher, E., Schneeberger, C., Tschugguel, W., Eder, S., Sliutz, G., and Huber, J. C. Simultaneous expression of nitric oxide synthase and estrogen receptor in human breast cancer cell lines. Breast Cancer Res. Treat., 40: 205-207, 1996.
62. Martin, J. H., Begum, S., Alalami, O., Harrison, A., and Scott, K. W. Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer. Tumour Biol., 21: 90-97, 2000. (Pubitemid 30114654)
63. De Palo, G., Veronesi, U., Camerini, T., Formelli, F., Mascotti, G., Boni, C., Fosser, V., Del Vecchio, M., Campa, T., Costa, A., and Marubini, E. Can fenretinide protect women against ovarian cancer? J. Natl. Cancer Inst. (Bethesda), 87: 146-147, 1995.
64. Sabichi, A. L., Lerner, S. P., Grossman, H. B., and Lippman, S. M. Retinoids in the chemoprevention of bladder cancer. Curr. Opin. Oncol., 10: 479-484, 1998. (Pubitemid 28484374)
65. Clifford, J. L., Sabichi, A. L., Zou, C., Yang, X., Steele, V. E., Kelloff, G. J., Lotan, R., and Lippman, S. M. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol. Biomark. Prev., 10: 391-395, 2001. (Pubitemid 32703225)
66. Chiesa, F., Tradati, N., Marazza, M., Rossi, N., Boracchi, P., Mariani, L., Clerici, M., Formelli, F., Barzan, L., Carrassi, A., Pastorini, A., Camerini, T., Giardini, R., Zurrida, S., Minn, F. L., Costa, A., De Palo, G., and Veronesi, U. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Oral Oncol. Eur. J. Cancer, 28B: 97-102, 1992.
67. De Palo, G., Veronesi, U., Marubini, E., Camerini, T., Chiesa, F., Nava, M., Formelli, F., Del Vecchio, M., Costa, A., Boracchi, P., and Mariani, L. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. J. Cell. Biochem. Suppl., 22: 11-17, 1995.
68. Cobleigh, M. A., Dowlatshahi, K., Deutsch, T. A., Mehta, R. G., Moon, R. C., Minn, F., Benson, A. B., III, Rademaker, A. W., Ashenhurst, J. B., Wade, J. L., III, and Wolter, J. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J. Clin. Oncol., 11: 474-477, 1993. (Pubitemid 23071044)